Open Access Articles- Top Results for Bromantane


Systematic (IUPAC) name
Clinical data
  • US: Not approved
87913-26-6 7pxY
PubChem CID 4660557
ChemSpider 3849628 7pxN
Chemical data
Formula C16H20BrN
306.246 g/mol
 14pxN (what is this?)  (verify)

Bromantane (brand name Ladasten) is a stimulant drug with anxiolytic properties developed in Russia during the late 1980s,[1][2] which acts mainly by inhibiting the reuptake of both dopamine and serotonin in the brain,[3][4][5][6] although it also has anticholinergic effects at very high doses.[7][8] It was used as a doping agent to enhance athletic performance, and several athletes tested positive for the drug at the 1996 Atlanta Olympic Games,[9] following which it was added to the banned list as a stimulant and masking agent. Research on this class of drugs has been fairly extensive and a large family of derivatives are known, although bromantane remains the best studied,[10] and human trials continue for applications such as increasing endurance under extreme conditions.[11]

Study results suggest that the combination of psychostimulant and anxiolytic actions in the spectrum of psychotropic activity of bromantane is effective in treating asthenic disorders compared to placebo. It is considered novel having both stimulant and anti-anxiety properties.[12]


  1. ^ Krapivin, SV; Sergeeva, SA; Morozov, IS (1993). "A quantitative pharmaco-electroencephalographic analysis of the action of bromantane". Biulleten' eksperimental'noi biologii i meditsiny 116 (11): 515–8. PMID 8312546. 
  2. ^ I.S. Morozov, I.A. Ivanova and T.A. Lukicheva (2001). "Search for New Drugs: Actoprotector and Adaptogen properties of Adamantane Derivatives (A Review)". Pharma. Chem. J. 35 (5): 235–238. doi:10.1023/A:1011905302667. 
  3. ^ Grekhova, TV; Gaĭnetdinov, RR; Sotnikova, TD; Krasnykh, LM; Kudrin, VS; Sergeeva, SA; Morozov, IS (1995). "The effect of bromantane, a new immunostimulant with psychostimulating action, on release and metabolism of dopamine in the dorsal striatum of freely moving rats: A microdialysis study". Biulleten' eksperimental'noi biologii i meditsiny 119 (3): 302–4. PMID 7795203. 
  4. ^ Kudrin, VS; Sergeeva, SA; Krasnykh, LM; Miroshnichenko, II; Grekhova, TV; Gaĭnetdinov, RR (1995). "The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain". Eksperimental'naia i klinicheskaia farmakologiia 58 (4): 8–11. PMID 7580761. 
  5. ^ Morozov, IS; Pukhova, GS; Avdulov, NA; Sergeeva, SA; Spasov, AA; Iezhitsa, IN (1999). "The mechanisms of the neurotropic action of bromantan". Eksperimental'naia i klinicheskaia farmakologiia 62 (1): 11–4. PMID 10198757. 
  6. ^ Seredenin, SB; Miramedova, AG (1999). "Analysis of pharmacological properties of bromantane". Biulleten' eksperimental'noi biologii i meditsiny 128 (11): 529–31. PMID 10640239. 
  7. ^ Bugaeva, LI; Verovskiĭ, VE; Iezhitsa, IN; Spasov, AA (2000). "An acute toxicity study of bromantane". Eksperimental'naia i klinicheskaia farmakologiia 63 (1): 57–61. PMID 10763112. 
  8. ^ Iezhitsa, IN; Spasov, AA; Bugaeva, LI; Morozov, IS (2002). "Toxic effect of single treatment with bromantane on neurological status of experimental animals". Bulletin of experimental biology and medicine 133 (4): 380–3. PMID 12124651. 
  9. ^ Burnat, P; Payen, A; Le Brumant-Payen, C; Hugon, M; Ceppa, F (1997). "Bromontan, a new doping agent". Lancet 350 (9082): 963–4. PMID 9314900. doi:10.1016/s0140-6736(05)63310-7. 
  10. ^ Morozov, IS; Klimova, NV; Sergeeva, SA; Ivanova, IA; Barchukov, VG; Kovalev, GI; Piatin, BM; Avdiunina, NI (1999). "Adamantane derivatives enhancing body's resistance to emergencies". Vestnik Rossiiskoi akademii meditsinskikh nauk / Rossiiskaia akademiia meditsinskikh nauk (3): 28–32. PMID 10222828. 
  11. ^ Viatleva, OA; Barchukov, VG; Morozov, IS; Salenko, IuA; Zhirnov, EN (2000). "The neuro- and psychophysiological effects of bromantane". Voenno-meditsinskii zhurnal 321 (8): 61–5, 96. PMID 10998997. 
  12. ^ Neznamov, GG; Siuniakov, SA; Teleshova, SE; Chumakov, DV; Reutova, MA; Siuniakov, TS; Mametova, LE; Dorofeeva, OA; Grishin, SA (2009). "Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov 109 (5): 20–6. PMID 19491814. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.